These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27788856)

  • 21. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation.
    Patel HC; Hayward C; Ozdemir BA; Rosen SD; Krum H; Lyon AR; Francis DP; di Mario C
    Hypertension; 2015 Feb; 65(2):401-6. PubMed ID: 25403604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings.
    Esler M
    J Am Soc Hypertens; 2014 Aug; 8(8):593-8. PubMed ID: 25151320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
    Kandzari DE; Böhm M; Mahfoud F; Townsend RR; Weber MA; Pocock S; Tsioufis K; Tousoulis D; Choi JW; East C; Brar S; Cohen SA; Fahy M; Pilcher G; Kario K;
    Lancet; 2018 Jun; 391(10137):2346-2355. PubMed ID: 29803589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.
    Esler MD; Böhm M; Sievert H; Rump CL; Schmieder RE; Krum H; Mahfoud F; Schlaich MP
    Eur Heart J; 2014 Jul; 35(26):1752-9. PubMed ID: 24898552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
    Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
    Weber MA; Mahfoud F; Schmieder RE; Kandzari DE; Tsioufis KP; Townsend RR; Kario K; Böhm M; Sharp ASP; Davies JE; Osborn JW; Fink GD; Euler DE; Cohen DL; Schlaich MP; Esler MD
    JACC Cardiovasc Interv; 2019 Jun; 12(12):1095-1105. PubMed ID: 31221299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.
    Persu A; Kjeldsen S; Staessen JA; Azizi M
    Curr Hypertens Rep; 2016 Jan; 18(1):6. PubMed ID: 26739586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension.
    Weber MA; Kirtane AJ; Weir MR; Radhakrishnan J; Das T; Berk M; Mendelsohn F; Bouchard A; Larrain G; Haase M; Diaz-Cartelle J; Leon MB
    JACC Cardiovasc Interv; 2020 Feb; 13(4):461-470. PubMed ID: 32081240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating Hypertension Using Renal Artery Denervation: Problems and Progress.
    Townsend RR
    Adv Chronic Kidney Dis; 2019 Mar; 26(2):117-121. PubMed ID: 31023445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study.
    Rosa J; Widimský P; Toušek P; Petrák O; Čurila K; Waldauf P; Bednář F; Zelinka T; Holaj R; Štrauch B; Šomlóová Z; Táborský M; Václavík J; Kociánová E; Branny M; Nykl I; Jiravský O; Widimský J
    Hypertension; 2015 Feb; 65(2):407-13. PubMed ID: 25421981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study.
    Gosse P; Cremer A; Kirtane AJ; Lobo MD; Saxena M; Daemen J; Wang Y; Stegbauer J; Weber MA; Abraham J; Kario K; Bangalore S; Claude L; Liu Y; Azizi M
    Hypertension; 2021 Feb; 77(2):529-536. PubMed ID: 33356403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal sympathetic denervation in the aftermath of Symplicity HTN-3.
    Kjeldsen SE; Fadl Elmula FE; Persu A; Jin Y; Staessen JA
    Blood Press; 2014 Oct; 23(5):256-61. PubMed ID: 25212427
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Blood Pressure-Lowering Effect of Renal Denervation.
    Howard JP; Shun-Shin MJ; Hartley A; Bhatt DL; Krum H; Francis DP
    Circ Cardiovasc Qual Outcomes; 2016 Jan; 9(1):14-22. PubMed ID: 26758193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go?
    Briasoulis A; Bakris G
    Can J Cardiol; 2015 May; 31(5):642-8. PubMed ID: 25828371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
    Kandzari DE; Bhatt DL; Brar S; Devireddy CM; Esler M; Fahy M; Flack JM; Katzen BT; Lea J; Lee DP; Leon MB; Ma A; Massaro J; Mauri L; Oparil S; O'Neill WW; Patel MR; Rocha-Singh K; Sobotka PA; Svetkey L; Townsend RR; Bakris GL
    Eur Heart J; 2015 Jan; 36(4):219-27. PubMed ID: 25400162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial.
    Flack JM; Bhatt DL; Kandzari DE; Brown D; Brar S; Choi JW; D'Agostino R; East C; Katzen BT; Lee L; Leon MB; Mauri L; O'Neill WW; Oparil S; Rocha-Singh K; Townsend RR; Bakris G;
    J Am Soc Hypertens; 2015 Oct; 9(10):769-779. PubMed ID: 26362830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertension: is the sham procedure 'toxic' for renal denervation?
    Tsioufis C
    Nat Rev Nephrol; 2014 Apr; 10(4):186-7. PubMed ID: 24595040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistant hypertension and renal denervation. Considerations on the results of the SYMPLICITY HTN-3 trial.
    Ruilope LM; Arribas F
    Rev Esp Cardiol (Engl Ed); 2014 Nov; 67(11):881-2. PubMed ID: 25242659
    [No Abstract]   [Full Text] [Related]  

  • 39. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients - .
    Kario K; Ogawa H; Okumura K; Okura T; Saito S; Ueno T; Haskin R; Negoita M; Shimada K;
    Circ J; 2015; 79(6):1222-9. PubMed ID: 25912693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of catheter-based renal denervation on glycemic control and lipid levels: a systematic review and meta-analysis.
    Zhang Z; Liu K; Xiao S; Chen X
    Acta Diabetol; 2021 May; 58(5):603-614. PubMed ID: 33459896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.